Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells.

Carter BZ, Mak DH, Wang Z, Ma W, Mak PY, Andreeff M, Davis RE.

Leuk Res. 2013 Aug;37(8):974-9. doi: 10.1016/j.leukres.2013.04.018. Epub 2013 May 10.

2.

Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.

Rosato RR, Almenara JA, Kolla SS, Maggio SC, Coe S, Giménez MS, Dent P, Grant S.

Mol Cancer Ther. 2007 Feb;6(2):692-702.

4.

Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.

Bu R, Hussain AR, Al-Obaisi KA, Ahmed M, Uddin S, Al-Kuraya KS.

Leuk Lymphoma. 2014 Feb;55(2):415-24. doi: 10.3109/10428194.2013.806799. Epub 2013 Jun 24.

PMID:
23697845
5.

p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.

Piedfer M, Bouchet S, Tang R, Billard C, Dauzonne D, Bauvois B.

Biochim Biophys Acta. 2013 Jun;1833(6):1316-28. doi: 10.1016/j.bbamcr.2013.02.016. Epub 2013 Feb 26.

6.

The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.

Colado E, Alvarez-Fernández S, Maiso P, Martín-Sánchez J, Vidriales MB, Garayoa M, Ocio EM, Montero JC, Pandiella A, San Miguel JF.

Haematologica. 2008 Jan;93(1):57-66. doi: 10.3324/haematol.11666.

7.

Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.

Nencioni A, Wille L, Dal Bello G, Boy D, Cirmena G, Wesselborg S, Belka C, Brossart P, Patrone F, Ballestrero A.

Clin Cancer Res. 2005 Jun 1;11(11):4259-65.

8.

Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions.

Kahana S, Finniss S, Cazacu S, Xiang C, Lee HK, Brodie S, Goldstein RS, Roitman V, Slavin S, Mikkelsen T, Brodie C.

Cell Signal. 2011 Aug;23(8):1348-57. doi: 10.1016/j.cellsig.2011.03.017. Epub 2011 Mar 29.

PMID:
21440622
9.

Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8.

Laussmann MA, Passante E, Düssmann H, Rauen JA, Würstle ML, Delgado ME, Devocelle M, Prehn JH, Rehm M.

Cell Death Differ. 2011 Oct;18(10):1584-97. doi: 10.1038/cdd.2011.27. Epub 2011 Apr 1.

10.

Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.

Matondo M, Bousquet-Dubouch MP, Gallay N, Uttenweiler-Joseph S, Recher C, Payrastre B, Manenti S, Monsarrat B, Burlet-Schiltz O.

Leuk Res. 2010 Apr;34(4):498-506. doi: 10.1016/j.leukres.2009.09.020. Epub 2009 Oct 6.

PMID:
19811823
11.

Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.

Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, Goyama S, Jansen G, Cloos J, Rigolino C, Cortelezzi A, Mulloy JC, Oliva EN, Cuzzola M, Starczynowski DT.

Blood. 2012 Jul 26;120(4):858-67. doi: 10.1182/blood-2012-02-407999. Epub 2012 Jun 8. Erratum in: Blood. 2014 Jun 5;123(23):3682.

12.

High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.

Rushworth SA, Bowles KM, MacEwan DJ.

Cancer Res. 2011 Mar 1;71(5):1999-2009. doi: 10.1158/0008-5472.CAN-10-3018. Epub 2011 Jan 6.

13.

Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.

Dai Y, Chen S, Wang L, Pei XY, Kramer LB, Dent P, Grant S.

Br J Haematol. 2011 Apr;153(2):222-35. doi: 10.1111/j.1365-2141.2011.08591.x. Epub 2011 Mar 6.

14.

Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.

Liu CY, Shiau CW, Kuo HY, Huang HP, Chen MH, Tzeng CH, Chen KF.

Haematologica. 2013 May;98(5):729-38. doi: 10.3324/haematol.2011.050187. Epub 2012 Sep 14.

15.

Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML.

Carter BZ, Mak DH, Schober WD, Koller E, Pinilla C, Vassilev LT, Reed JC, Andreeff M.

Blood. 2010 Jan 14;115(2):306-14. doi: 10.1182/blood-2009-03-212563. Epub 2009 Nov 6.

16.

Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.

Bosman MC, Schuringa JJ, Quax WJ, Vellenga E.

Exp Hematol. 2013 Jun;41(6):530-538.e1. doi: 10.1016/j.exphem.2013.02.002. Epub 2013 Feb 13.

PMID:
23416210
17.

The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.

Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS.

Mol Cancer Ther. 2005 Mar;4(3):443-9.

18.

Heat-shock protein 70 antisense oligomers enhance proteasome inhibitor-induced apoptosis.

Robertson JD, Datta K, Biswal SS, Kehrer JP.

Biochem J. 1999 Dec 1;344 Pt 2:477-85.

19.

Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells.

Merhi F, Tang R, Piedfer M, Mathieu J, Bombarda I, Zaher M, Kolb JP, Billard C, Bauvois B.

PLoS One. 2011;6(10):e25963. doi: 10.1371/journal.pone.0025963. Epub 2011 Oct 6.

20.
Items per page

Supplemental Content

Write to the Help Desk